Anaplastic lymphoma kinase proteins in growth control and cancer

被引:172
作者
Pulford, K
Morris, SW
Turturro, F
机构
[1] Univ Oxford, John Radcliffe Hosp, Leukaemia Res Fund, Immunodiagnost Unit,Nuffield Dept Clin Lab Sci, Oxford OX3 9DU, England
[2] St Jude Childrens Res Hosp, Dept Pathol, Memphis, TN 38105 USA
[3] St Jude Childrens Res Hosp, Dept Hematol Oncol, Memphis, TN 38105 USA
[4] LSU, Ctr Hlth Sci, Feist Weiller Canc Ctr, Dept Med, Shreveport, LA USA
关键词
D O I
10.1002/jcp.10472
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
The normal functions of full-length anaplastic lymphoma kinase (ALK) remain to be completely elucidated. Although considered to be important in neural development, recent studies in Drosophila also highlight a role for ALK in gut muscle differentiation. Indeed, the Drosophila model offers a future arena for the study of ALK, its ligands and signalling cascades. The discovery of activated fusion forms of the ALK tyrosine kinase in anaplastic large cell lymphoma (ALCL) has dramatically improved our understanding of the pathogenesis of these lymphomas and enhanced the pathological diagnosis of this subtype of non-Hodgkin's lymphoma (NHL). Likewise, the realisation that a high percentage of inflammatory myofibro-blastic tumours express activated-ALK fusion proteins has clarified the causation of these mesenchymal neoplasms and provided for their easier discrimination from other mesenchymal-derived inflammatory myofibroblastic tumour (IMT) mimics. Recent reports of ALK expression in a range of carcinoma-derived cell lines together with its apparent role as a receptor for PTN and MK, both of which have been implicated in tumourigenesis, raise the possibility that ALK-mediated signalling could play a role in the development and/or progression of a number of common solid tumours. The therapeutic targeting of ALK may prove to have efficacy in the treatment of many of these neoplasms. J. Cell. Physiol. 199: 330-358, 2004. (C) 2004 Wiley-Liss, Inc.
引用
收藏
页码:330 / 358
页数:29
相关论文
共 331 条
[71]  
ENGLUND C, 2003, IN PRESS NATURE
[72]   Inactivation of the forkhead transcription factor FoxO3 is essential for PKB-mediated survival of hematopoietic progenitor cells by kit ligand [J].
Engström, M ;
Karlsson, R ;
Jönsson, JI .
EXPERIMENTAL HEMATOLOGY, 2003, 31 (04) :316-323
[73]   Inhibition of tyrosine kinase activity induces caspase-dependent apoptosis in anaplastic large cell lymphoma with NPM-ALK (p80) fusion protein [J].
Ergin, M ;
Denning, MF ;
Izban, KF ;
Amin, HM ;
Martinez, RL ;
Saeed, S ;
Alkan, S .
EXPERIMENTAL HEMATOLOGY, 2001, 29 (09) :1082-1090
[74]  
Falini B, 1999, BLOOD, V93, P2697
[75]   ALK expression defines a distinct group of T/null lymphomas ("ALK lymphomas") with a wide morphological spectrum [J].
Falini, B ;
Bigerna, B ;
Fizzotti, M ;
Pulford, K ;
Pileri, SA ;
Delsol, G ;
Carbone, A ;
Paulli, M ;
Magrini, U ;
Menestrina, F ;
Giardini, R ;
Pilotti, S ;
Mezzelani, A ;
Ugolini, B ;
Billi, M ;
Pucciarini, A ;
Pacini, R ;
Pelicci, PG ;
Flenghi, L .
AMERICAN JOURNAL OF PATHOLOGY, 1998, 153 (03) :875-886
[76]   Proteins encoded by genes involved in chromosomal alterations in lymphoma and leukemia: clinical value of their detection by immunocytochemistry [J].
Falini, B ;
Mason, DY .
BLOOD, 2002, 99 (02) :409-426
[77]   Anaplastic large cell lymphoma: Pathological, molecular and clinical features [J].
Falini, B .
BRITISH JOURNAL OF HAEMATOLOGY, 2001, 114 (04) :741-760
[78]  
Falini B, 1999, BLOOD, V94, P3509
[79]  
FALINI B, 1995, BLOOD, V87, P3437
[80]  
FANG WJ, 1992, J BIOL CHEM, V267, P25889